Galapagos (GLPG) Stock Forecast, Price & News

Galapagos (NASDAQ:GLPG) Frequently Asked Questions

Is Galapagos a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Galapagos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View analyst ratings for Galapagos or view top-rated stocks.

When is Galapagos' next earnings date?

Galapagos is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Galapagos.

What price target have analysts set for GLPG?

9 Wall Street analysts have issued 1-year price objectives for Galapagos' stock. Their forecasts range from $50.00 to $80.00. On average, they expect Galapagos' share price to reach $65.97 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price.
View analysts' price targets for Galapagos or view top-rated stocks among Wall Street analysts.

Who are Galapagos' key executives?

Galapagos' management team includes the following people:

• Mr. Bart Filius M.B.A., MBA, Pres, COO & Member of Management Board (Age 52, Pay $851.07k)
• Dr. Andre Hoekema, Chief Bus. Officer & Member of Management Board (Age 65, Pay $599.66k)
• Dr. Walid Abi-Saab, Chief Medical Officer & Member of Management Board (Age 57, Pay $708.34k)
• Mr. Michele Manto M.B.A., Chief Commercial Officer & Member of Management Board
• Dr. Paulus A. Stoffels M.D., Ph.D., Chief Exec. Officer (Age 60)
• Ms. Elizabeth Goodwin, VP of Investor Relations
• Ms. Sofie Van Gijsel, Head of Investor Relations
• Marieke Vermeersch, Head of Corp. Communication
• John Montana, Managing Director of Argenta
• Ms. Chantal Tasset, Head of Devel.

What is Onno van de Stolpe's approval rating as Galapagos' CEO?

6 employees have rated Galapagos CEO Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among Galapagos' employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Galapagos' key competitors?

Some companies that are related to Galapagos include BioMarin Pharmaceutical (BMRN), Viatris (VTRS), BeiGene (BGNE), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Biohaven Pharmaceutical (BHVN), Jazz Pharmaceuticals (JAZZ), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Maravai LifeSciences (MRVI), Legend Biotech (LEGN) and Sarepta Therapeutics (SRPT).
View all of GLPG's competitors.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

When did Galapagos IPO?

(GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is Galapagos' stock symbol?

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Who are Galapagos' major shareholders?

Galapagos' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.79%), Great Point Partners LLC (0.55%), JPMorgan Chase & Co. (0.46%), Greenlight Capital Inc. (0.24%), Renaissance Technologies LLC (0.13%) and Goldman Sachs Group Inc. (0.10%).

Which institutional investors are selling Galapagos stock?

GLPG stock was sold by a variety of institutional investors in the last quarter, including Silverarc Capital Management LLC, Monaco Asset Management SAM, UBS Group AG, HAP Trading LLC, Greenlight Capital Inc., Goldman Sachs Group Inc., Quantbot Technologies LP, and Citigroup Inc..

Which institutional investors are buying Galapagos stock?

GLPG stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Great Point Partners LLC, Endurant Capital Management LP, Arrowstreet Capital Limited Partnership, Jane Street Group LLC, Renaissance Technologies LLC, Simplex Trading LLC, and Group One Trading L.P..

How do I buy shares of Galapagos?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galapagos' stock price today?

One share of GLPG stock can currently be purchased for approximately $56.95.

How much money does Galapagos make?

Galapagos has a market capitalization of $3.74 billion and generates $573.66 million in revenue each year.

How many employees does Galapagos have?

Galapagos employs 1,309 workers across the globe.

What is Galapagos' official website?

The official website for Galapagos is www.glpg.com.

How can I contact Galapagos?

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at (321) 534-2900, via email at [email protected], or via fax at 321-534-2901.